ANDA 77491, held by Pharmazone. Pravastatin Sodium.
As of Nov 16, 2026, ANDA 77491 (Pravastatin Sodium), held by Pharmazone, was first approved by FDA on Feb 11, 2008, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 11, 2008 | Original application | Approved | None posted |
| Pravastatin Sodium80MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium10MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium20MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium40MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium30MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium60MG · tablet;oral | Pravastatin Sodium | Rx |
| Aug 6, 2026 | Supplement 7Manufacturing | Approved | None posted |
| Feb 6, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 9, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 1, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 1, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 2, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 11, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters